Incidence of Interstitial Lung Disease (ILD) in Users of ACTEMRA® (Tocilizumab), Rituxan® (Rituximab), Abatacept and Anti-Tumor Necrosis Factor Alpha Agents First published 08/12/2016 Last updated 02/04/2024 EU PAS number:EUPAS16482 Study Finalised